# RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment

> **NCT06409832** · — · RECRUITING · sponsor: **University of Florence** · enrollment: 100 (estimated)

## Conditions studied

- Migraine
- Migraine With Aura
- Migraine Without Aura
- Chronic Migraine

## Interventions

- **DRUG:** Rimegepant 75 mg

## Key facts

- **NCT ID:** NCT06409832
- **Lead sponsor:** University of Florence
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-26
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409832, "RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06409832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*